The use of tumor genome profiling to identify actionable or targetable mutations in women with breast cancer is not ready for routine use in clinical practice.
As more treatment options become available for metastatic HER2-positive breast cancer, some questions regarding the optimal sequencing of therapies remain.
In this video we discuss two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.
The idea that breast cancer is overdiagnosed is being perpetuated in an effort to reduce access to breast cancer screening, according to a presentation at MBCC.
In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.
A physician’s age may have an effect on his or her opinions about the effectiveness of breast cancer screening methods, including self-exam and mammography.
Women with hormone receptor-positive breast cancer may be more scared, anxious, or concerned about treatment-related adverse events and cancer symptoms.
At MBCC, one presenter made the argument for screening mammography for all women starting at the age of 40, despite the controversy surrounding the topic.
According to a presentation at MBCC, modern breast cancer staging systems should include grade, estrogen receptor status, and possibly other biologic markers.
Women with breast cancer who received first-line eribulin were able to stay on treatment longer and had better outcomes when they received dose modifications.